Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apollomics Inc

6.80
+0.0000
Volume:572.00
Turnover:3.74K
Market Cap:7.50M
PE:-0.13
High:6.80
Open:6.80
Low:6.80
Close:6.80
Loading ...

Company Profile

Company Name:
Apollomics Inc
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
13
Office Location:
989 East Hillsdale Blvd,Suite 220,Foster City,California,United States
Zip Code:
94404
Fax:
650 288 1674
Introduction:
Apollomics, Inc., a biopharmaceutical company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China; and Southbank, Australia.

Directors

Name
Position
Guo Liang Yu
Chairman of the Board and Chief Executive Officer
Chen, Hong Jung
Director
Glenn S. Vraniak
Director
Kenneth C. Carter
Director
Robert Lin
Director
Sanjeev Redkar
Director
Wendy Hayes
Director

Shareholders

Name
Position
Guo Liang Yu
Chairman of the Board and Chief Executive Officer
Matthew Plunkett
Chief Financial Officer